Saif Al‐Chalabi

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Community- versus hospital-acquired acute kidney injury in hospitalised COVID-19 patients

Jack Bell, Ben James, Saif Al‐Chalabi et al. · BMC Nephrology · 2021 · 27 citations · Full text

Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases

Saif Al‐Chalabi, Akheel A. Syed, Philip A. Kalra et al. · Cardiorenal Medicine · 2024 · 15 citations · Full text

Managing acute presentations of atheromatous renal artery stenosis

Áine de Bhailis, Saif Al‐Chalabi, Rodrigo Hagemann et al. · BMC Nephrology · 2022 · 10 citations · Full text